Literature DB >> 29611177

Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study.

Brian K Link1, Bann-Mo Day2, Xiaolei Zhou3, Andrew D Zelenetz4, Keith L Dawson2, James R Cerhan5, Christopher R Flowers6, Jonathan W Friedberg7.   

Abstract

Entities:  

Keywords:  B-cell neoplasms; clinical results in lymphoma; immunotherapeutic approaches; rituximab; treatment patterns

Mesh：

Year:  2018        PMID： 29611177     DOI： 10.1111/bjh.15149

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  12 in total

Review 1.  Follicular lymphoma: is there an optimal way to define risk?

Authors:  Carla Casulo
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

2.  Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study.

Authors:  Carla Casulo; Melissa C Larson; Julianne J Lunde; Thomas M Habermann; Izidore S Lossos; Yucai Wang; Loretta J Nastoupil; Christopher Strouse; Dai Chihara; Peter Martin; Jonathon B Cohen; Brad S Kahl; W Richard Burack; Jean L Koff; Yong Mun; Anthony Masaquel; Mei Wu; Michael C Wei; Ashwini Shewade; Jia Li; James Cerhan; Christopher R Flowers; Brian K Link; Matthew J Maurer
Journal:  Lancet Haematol       Date:  2022-04       Impact factor: 30.153

3.  Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial.

Authors:  Nathan Hale Fowler; Michael Dickinson; Martin Dreyling; Joaquin Martinez-Lopez; Arne Kolstad; Jason Butler; Monalisa Ghosh; Leslie Popplewell; Julio C Chavez; Emmanuel Bachy; Koji Kato; Hideo Harigae; Marie José Kersten; Charalambos Andreadis; Peter A Riedell; P Joy Ho; José Antonio Pérez-Simón; Andy I Chen; Loretta J Nastoupil; Bastian von Tresckow; Andrés José María Ferreri; Takanori Teshima; Piers E M Patten; Joseph P McGuirk; Andreas L Petzer; Fritz Offner; Andreas Viardot; Pier Luigi Zinzani; Ram Malladi; Aiesha Zia; Rakesh Awasthi; Aisha Masood; Oezlem Anak; Stephen J Schuster; Catherine Thieblemont
Journal:  Nat Med       Date:  2021-12-17       Impact factor: 87.241

4.  Treatment Patterns and Health Care Costs in Commercially Insured Patients with Follicular Lymphoma.

Authors:  Nathan H Fowler; Guifang Chen; Stephen Lim; Stephanie Manson; Qiufei Ma; Frank Yunfeng Li
Journal:  J Health Econ Outcomes Res       Date:  2020-09-04

Review 5.  The role of axicabtagene ciloleucel as a treatment option for patients with follicular/marginal zone lymphoma.

Authors:  Jose Sandoval-Sus; Julio C Chavez
Journal:  Ther Adv Hematol       Date:  2021-05-29

6.  Prospects in the management of patients with follicular lymphoma beyond first-line therapy.

Authors:  David Qualls; Gilles Salles
Journal:  Haematologica       Date:  2022-01-01       Impact factor: 9.941

7.  New Indications and platforms for CAR-T therapy in lymphomas beyond DLBCL.

Authors:  Madiha Iqbal; Bipin N Savani; Mehdi Hamadani
Journal:  EJHaem       Date:  2021-11-23

Review 8.  Follicular lymphoma: updates for pathologists.

Authors:  Mahsa Khanlari; Jennifer R Chapman
Journal:  J Pathol Transl Med       Date:  2021-12-27

9.  Lifetime Costs for Treated Follicular Lymphoma Patients in the US.

Authors:  Caitlin Eichten; Qiufei Ma; Thomas E Delea; May Hagiwara; Roberto Ramos; Şerban R Iorga; Jie Zhang; Richard T Maziarz
Journal:  Pharmacoeconomics       Date:  2021-07-17       Impact factor: 4.981

10.  Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era.

Authors:  Raphael Mwangi; Stephen M Ansell; Thomas M Habermann; James R Cerhan; Christopher Strouse; Brian K Link; Yucai Wang; Rebecca L King; William R Macon; J C Villasboas; Thomas E Witzig; Matthew J Maurer; Grzegorz S Nowakowski
Journal:  Blood Cancer J       Date:  2021-07-17       Impact factor: 11.037
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.